We assumed that metabolism in the pancreas is more rapid than in the tumor, which is why at early time points the less stable GRPR-targeted peptides exhibited an accelerated clearance from the pancreas but not from the tumor, compared to more stable analogues. The gene discussed is GRPR; the disease is neoplasm.